Rhythm Pharmaceuticals Inc (RYTM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong growth potential in the rare genetic obesity market, positive financial trends, and analyst optimism outweigh the short-term technical and hedge fund selling concerns.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 41.376, and moving averages are converging, showing no clear momentum. The stock is trading near its pivot point of 99.604, with support at 95.975 and resistance at 103.233.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts are highly optimistic, with multiple price target increases and ratings of Buy or Outperform. RBC Capital projects over $2B in revenue by
Positive financial performance in Q4 2025, with revenue growth of 36.87% YoY and gross margin improvement to 91.61%.
Promising Phase 2 data for setmelanotide in Prader-Willi Syndrome, with analysts expecting regulatory approval and significant commercial potential.

Neutral/Negative Catalysts

Hedge funds are selling, with a 288.14% increase in selling activity last quarter.
Technical indicators show a bearish trend with no clear upward momentum.
No recent congress trading data or significant insider buying activity.

Financial Performance

In Q4 2025, Rhythm Pharmaceuticals reported revenue of $57.25M, a 36.87% YoY increase. Net income improved to -$48.84M, up 9.42% YoY. EPS increased to -0.73, up 1.39% YoY. Gross margin rose to 91.61%, up 0.73% YoY, indicating strong operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are overwhelmingly positive, with multiple price target increases ranging from $123 to $478. RBC Capital initiated coverage with an Outperform rating, citing strong growth potential in the rare genetic obesity market. Other analysts highlight the promising Phase 2 data for setmelanotide and its potential to expand into a blockbuster opportunity.

15 Analyst Rating

Wall Street analysts forecast RYTM stock price to rise

14 Buy

1 Hold

0 Sell

Strong Buy

Current: 92.730

Low

123

Averages

140.62

High

167

Current: 92.730

Low

123

Averages

140.62

High

167

Canaccord

Buy

maintain

$141 -> $140

AI Analysis

2026-03-02

New

Reason

Canaccord

Price Target

$141 -> $140

AI Analysis

2026-03-02

New

maintain

Buy

Reason

Canaccord lowered the firm's price target on Rhythm Pharmaceuticals to $140 from $141 and keeps a Buy rating on the shares. The firm said its 4Q report was incremental following the company's preannouncement earlier this year. On the commercial front, IMCIVREE revenue increased sequentially, driven by growth in BBS points, and the firm is encouraged by the company's prep for the launch of IMCIVREE in HO ahead of the March 20 PDUFA goal date.

Citizens

Outperform

maintain

$167 -> $176

2026-02-27

New

Reason

Citizens

Price Target

$167 -> $176

2026-02-27

New

maintain

Outperform

Reason

Citizens raised the firm's price target on Rhythm Pharmaceuticals to $176 from $167 and keeps an Outperform rating on the shares. Following a January preannouncement, Rhythm's top line held no surprises, with continued strong Imcivree growth expected in 2026, supported by a likely hypothalamic obesity approval next month and a well-prepared launch into a 10K U.S. patient population, where extension-trial conversions alone could add meaningful upside to the $290M HO sales estimate, the analyst tells investors in a research note. Multiple upcoming catalysts, including EMANATE and Japanese data readouts, the HO PDUFA, additional bivamelagon Phase 3 details, and a mid-2026 Prader-Willi Syndrome update, reinforce confidence in long-term growth potential and position Rhythm as a compelling smid-cap opportunity, the firm says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RYTM

Unlock Now

RYTM Should I Buy

RYTM Should I Buy

Should You Buy Rhythm Pharmaceuticals Inc (RYTM) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch